RxDoctor Payments Data

Patrick Haugh, MD

Internal Medicine · Clinton, MDNPI 1235122680

Payments from drug & device makers

$1,157in general payments, 2019–2025

Across 66 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$820
  • Gilead$206
  • Johnson & Johnson$39
  • Theratechnologies Inc.$36
  • Dexcom, Inc.$20
  • Merck$19
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,157 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$70,181
Medicare patients
250
Services billed
813

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala414$1,803,223
OdefseyEmtricitab/Rilpiviri/Tenof Ala164$747,755
DovatoDolutegravir Sodium/Lamivudine234$742,410
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$231,628
GenvoyaElviteg/Cob/Emtri/Tenof Alafen37$200,861
JulucaDolutegravir/Rilpivirine37$134,237
TivicayDolutegravir Sodium36$129,537
TrogarzoIbalizumab-Uiyk17$117,839
DescovyEmtricitabine/Tenofov Alafenam50$117,019
RukobiaFostemsavir Tromethamine14$115,625
PrezcobixDarunavir/Cobicistat37$90,404
TriumeqAbacavir/Dolutegravir/Lamivudi12$64,933
IsentressRaltegravir Potassium26$55,402
CompleraEmtricita/Rilpivirine/Tenof Df15$54,531
Darunavir25$32,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$206$2,121,103501 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Rukobia, Triumeq$820$1,186,742333 claims
Johnson & JohnsonPrezcobix, Complera$39$144,93552 claims
Theratechnologies Inc.Trogarzo$36$117,83917 claims
MerckIsentress$19$55,40226 claims
AbbVieLinzess$16$6,34712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Clinton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →